2018
Overview
Fragment Based Drug Design is a method in pharmaceutical research where small chemical fragments, typically with molecular weights below 300 Daltons, are identified and optimized as starting points for developing larger drug molecules. Research published in Advanced Pharmaceutical Science and Technology has explored computational and experimental approaches to drug design, examining the integration of in silico modeling, in vitro laboratory testing, and in vivo animal studies to advance pharmaceutical development. The journal has also published work on analytical characterization techniques relevant to drug molecules, including the application of liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry for detailed molecular analysis of pharmaceutical compounds such as metronidazole, demonstrating methods to assess isotopic abundance ratios and structural properties. This topic matters because fragment-based approaches can identify novel chemical scaffolds that might be overlooked by traditional high-throughput screening, potentially leading to more efficient drug discovery processes with improved binding affinity and selectivity. The combination of computational prediction, experimental validation, and advanced analytical techniques represents an evolving toolkit for pharmaceutical scientists working to develop new therapeutic agents.
Research published in this journal
2 peer-reviewed articles, ranked by relevance. Each links to its DOI.
2020
How this research is being cited
The 2 articles above have been cited 2 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Oct 2025.
-
Caio Cesar Candido et al. · 2022 · Journal of Inorganic Biochemistry
-
B. Ivanova et al. · 2022 · Analytical Chemistry Letters
A sample of recent works citing this journal's research on Fragment Based Drug Design, linking to each citing work.